Know Labs (NYSE:KNW) announced today that it received a new patent equating its diagnostic technology to the current glucose monitoring standard.
Seattle-based Know Labs develops the Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. It integrate into wearable, mobile or bench-top form factors. The first application of the technology comes in the form of a non-invasive glucose monitor.
The company’s new patent equates the technology to mean absolute relative difference, or MARD. This standard, used by diabetes researchers and glucose meter makers, establishes a range of clinical accuracy. Know Labs said the patent expands its IP portfolio to nearly 90 patents issued and pending.
Get the full story at our sister site, Drug Delivery Business News.